Zhengye Biotechnology Holding Ltd
ZYBTNasdaq
$0.70
↓ -7.5%Jul 17 close · end-of-day
Price
1Y↓ -23.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$33.1M
Enterprise Value
$34.2M
P/E
—
P/S
2.0
P/B
0.9
EV/EBITDA
—
PEG
—
FCF Yield
5.3%
Dividend Yield
—
Revenue (TTM)
$16.6M
Net Income (TTM)
-$10.0M
Free Cash Flow (TTM)
$1.8M
Gross Margin
20.5%
Operating Margin
-60.6%
Net Margin
-60.0%
ROE
-27.9%
ROIC
-21.6%
Debt / Equity
0.0
Net Cash
-$1.1M
Return 1Y
—
Company profile
We, through the operating entity, focus on the research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. For nearly 20 years, the operating entity has been committed to enhancing the health of livestock. The operating entity markets a diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The operating entity’s products are available in 29 provincial regions across China and are exported overseas, to Vietnam, Pakistan, and Egypt. Our principal executive offices are located at No.1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin Province, China. Our registered office in the Cayman Islands is located at 3-212 Governors Square, 23 Lime Tree Bay Avenue, P.O. Box 30746, Seven Mile Beach, Grand Cayman KY1-1203, Cayman Islands. Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY 10168.
- CEO
- Songlin Song
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 278
- Website
- www.jlzybio.com
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | $25.5M | $16.6M |
| Gross profit | — | — | $12.5M | $3.4M |
| Operating income | — | — | $2.3M | -$10.1M |
| Net income | — | — | $1.6M | -$10.0M |
| Diluted EPS | — | — | $0.03 | — |
| Operating cash flow | — | — | $5.6M | $1.9M |
| Free cash flow | — | — | $3.8M | $1.8M |
| Gross margin | — | — | 49.0% | 20.5% |
| Operating margin | — | — | 8.8% | -60.6% |
| Net margin | — | — | 6.1% | -60.0% |
No quarterly data.
Company news
Apr 28, 2026
Feb 10, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.